Hal Bar­ron keeps 23andMe close on GSK's side to find more genes the R&D team can go af­ter

Four years af­ter first en­list­ing 23andMe on a jour­ney of tar­get dis­cov­ery, Hal Bar­ron wants to keep go­ing.

Glax­o­SmithK­line has ex­er­cised its op­tion to ex­tend …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER